Noregen Tag

Rochester, MI, USA, July 17, 2023 – Caeregen Therapeutics announced today that it has been awarded a $1.4 million Phase 2 Small Business Innovation Research (SBIR) grant from the National Institutes of Health (NIH) and National Eye Institute (NEI) to advance the development of CTR-107 (Noregen™),...

Advancing treatments for retinal-related vision loss and other neurosensory diseases Rochester, MI and Chapel Hill, NC, August 12, 2021 – Retinal Solutions, LLC, a Michigan-based, regenerative medicine therapeutics company, today announced it has changed its name to Caeregen Therapeutics, LLC. The progression into pharmaceutical development of Noregen™, the...